Insider Transactions in Q4 2025 at Pharma Cyte Biotech, Inc. (PMCB)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 12
2025
|
Michael M Abecassis Director |
SELL
Payment of exercise price or tax liability
|
Direct |
16,875
-43.08%
|
$16,875
$1.02 P/Share
|
|
Dec 12
2025
|
Michael M Abecassis Director |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+48.91%
|
-
|
|
Dec 12
2025
|
Jonathan Schechter Director |
SELL
Payment of exercise price or tax liability
|
Direct |
67,500
-33.75%
|
$67,500
$1.02 P/Share
|
|
Dec 12
2025
|
Jonathan Schechter Director |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+42.86%
|
-
|
|
Dec 12
2025
|
Joshua Silverman CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
258,750
-45.0%
|
$258,750
$1.02 P/Share
|
|
Dec 12
2025
|
Joshua Silverman CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
575,000
+50.0%
|
-
|
|
Dec 12
2025
|
Wayne Remell Walker Director |
SELL
Payment of exercise price or tax liability
|
Direct |
16,875
-45.0%
|
$16,875
$1.02 P/Share
|
|
Dec 12
2025
|
Wayne Remell Walker Director |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+50.0%
|
-
|
|
Dec 12
2025
|
Robert Weinstein Director |
SELL
Payment of exercise price or tax liability
|
Direct |
33,750
-45.0%
|
$33,750
$1.02 P/Share
|
|
Dec 12
2025
|
Robert Weinstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+50.0%
|
-
|